Navigation Links
Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
Date:11/7/2012

Research and Development at Biogen Idec.  He joined Biogen Idec from ZymoGenetics Inc., where he was most recently CEO and member of the Board of Directors. Previously, he held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics Inc., and Senior Vice President and Washington Site Leader at Amgen Inc. Dr. Williams also served in a series of scientific and senior leadership positions over a decade at Immunex Corp., including Executive Vice President and Chief Technology Officer, Senior Vice President of Discovery Research and Vice President of Research and Development.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
2. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
3. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
4. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
5. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
6. Aushon BioSystems Appoints Bill Williams Vice President of Sales
7. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
8. Igenica Appoints Mary Haak-Frendscho, Ph.D., as Chief Executive Officer
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
11. Pharmalink Consulting Appoints Chief Operating Officer for the Americas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Conn., Sept. 21 In a platform presentation at ... the Study of Diabetes (EASD) in Stockholm, investigators for ... the results of a clinical study evaluating a new ... (Profil Institute for Metabolic Research, Neuss, Germany) and colleagues ...
... Inc. (Nasdaq: VVUS ) today announced positive ... Controlled Release Capsules, an investigational therapy for treatment of ... Americans. The findings come from the ... subset of patients who completed the previously reported 56-week ...
Cached Medicine Technology:Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 2Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 2New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 3New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 4New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 5New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years 6
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... TORONTO, April 24, 2014 Pregnant immigrants from ... require increased monitoring during pregnancy, according to new ... published today in the British Journal of ... preeclampsia and eclampsia rates among immigrants and native-born ... Canada (Ontario), Denmark, Sweden, Spain (Catalonia and Valencia) ...
(Date:4/23/2014)... American Society for Radiation Oncology (ASTRO) has issued ... Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline," ... in the treatment of endometrial cancer. The guideline,s ... issue of Practical Radiation Oncology (PRO), ... full-length guideline is available as an open-access article ...
(Date:4/23/2014)... of the gastro-intestinal tract has long been considered to ... the Sahlgrenska Academy have used refined microscopic techniques that ... surface of the gastro-intestinal tract is only as large ... , The digestive tract, which passes from the mouth ... a length of about 5 meters in a normal ...
(Date:4/23/2014)... the potential health benefits of probiotics, antioxidants and other ... And the chemical industry is getting in on the ... deter growth, so the industry is responding with clinical ... cover story in Chemical & Engineering News ... Society. , Melody M. Bomgardner, a senior editor at ...
Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... , WASHINGTON , Jan. 29 In today,s ... Bipartisan Policy Center,s (BPC) plan for reforming health care, entitled: ... as a bipartisan health care proposal that is worthy of ... plan, which was developed by former U.S. Senate Majority Leaders ...
... more likely to strike whites than blacks, researchers find , ... its kind finds that Parkinson,s disease in the United States ... whites and Hispanics are twice as likely to develop the ... an analysis of data from 36 million Medicare recipients, are ...
... The Minnesota Medical Association Board of Trustees decided Saturday ... Assistance Medical Care (GAMC) program, but not if such efforts include ... not cover the cost of providing care. , The Board also ... programs. The MMA sent a letter to lawmakers this week. , ...
... New collaboration leverages Joslin,s deep clinical and research expertise and ... BOSTON , Jan. 29 Joslin.org ... Center, the world,s preeminent diabetes research and clinical care organization, and ... with diabetes, today announced a new online partnership. dLife will ...
... quite some time, the "Holy Grail" in medical imaging has ... death as a means to intervene early in diseases and ... researchers at the University of Notre Dame and the Washington ... synthetic probe to target dead and dying cells in mammary ...
... Both ... symptoms of autism with a Biomedical alternative. , ... (PRWEB) January 29, 2010 -- Autism-supplements.com, a Lyndhurst New ... Jenny McCarthy and Jim Carrey’s autism organization, to help raise money and public awareness ...
Cached Medicine News:Health News:President Obama Highlights Bipartisan Policy Center Health Care Reform Plan in Remarks to House Republicans 2Health News:President Obama Highlights Bipartisan Policy Center Health Care Reform Plan in Remarks to House Republicans 3Health News:Parkinson's More Common in Northeast, Midwest 2Health News:Doctors Tell Lawmakers to Find a New GAMC Fix 2Health News:Joslin Diabetes Center and dLife Form New Online Partnership 2Health News:Joslin Diabetes Center and dLife Form New Online Partnership 3Health News:New paper describes important advance in imaging of cell death 2Health News:Autism-Supplements.com and Generation Rescue Work Together to Raise Money for Biomedical Autism Treatments 2
... Aestiva/5 Pendant anesthesia machine offers proven ... range with the SmartVent ventilator. However, ... superior ventilation. Enhancements in flexibility, ergonomics ... in anesthesia delivery., ,The Aestiva/5 ...
With its integrated design and superior build quality each Prima SP is custom built to meet your requirements....
... Tegagel hydrogel wound filler and ... are amorphous hydrogel dressings specially formulated ... that has been shown to enhance ... formula meets clinical needs for management ...
Features various cylinder sizes and a simple two-handed pumping mechanism....
Medicine Products: